Prometheus Biosciences Inc logo

RXDX

Prometheus Biosciences Inc

$48.43

Earnings Summary

Revenue
$3.92Mn
Net Profits
$-32.07Mn
Net Profit Margins
-818.22%

Highlights

Revenue:

Prometheus Biosciences Inc’s revenue jumped 415.66% since last year same period to $3.92Mn in the Q1 2022. On a quarterly growth basis, Prometheus Biosciences Inc has generated 1428.47% jump in its revenue since last 3-months.

Net Profits:

Prometheus Biosciences Inc’s net profit fell -129.95% since last year same period to $-32.07Mn in the Q1 2022. On a quarterly growth basis, Prometheus Biosciences Inc has generated -7.18% fall in its net profits since last 3-months.

Net Profit Margins:

Prometheus Biosciences Inc’s net profit margin jumped 55.41% since last year same period to -818.22% in the Q1 2022. On a quarterly growth basis, Prometheus Biosciences Inc has generated -108.07% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Prometheus Biosciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.79
EPS Estimate Current Year
-0.79

Highlights

EPS Estimate Current Quarter:

Prometheus Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.79 - a -16.18% fall from last quarter’s estimates.

EPS Estimate Current Year:

Prometheus Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.79.

Key Ratios

Key ratios of the Prometheus Biosciences Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.82
Return on Assets (ROA)
-0.26
Return on Equity (ROE)
-0.52
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Prometheus Biosciences Inc’s earning per share (EPS) jumped 50.9% since last year same period to -0.82 in the Q1 2022. This indicates that the Prometheus Biosciences Inc has generated 50.9% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Prometheus Biosciences Inc’s return on assets (ROA) stands at -0.26.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Prometheus Biosciences Inc’s return on equity (ROE) stands at -0.52.

Dividend Per Share (DPS):

Prometheus Biosciences Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.79
-0.82
-3.8%

Company Information

Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.

Organisation
Prometheus Biosciences Inc
Employees
26